Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
female (5) 5
humans (5) 5
breast neoplasms - drug therapy (4) 4
breast neoplasms - pathology (4) 4
index medicus (4) 4
adult (3) 3
breast cancer (3) 3
disease-free survival (3) 3
middle aged (3) 3
oncology (3) 3
patients (3) 3
aged (2) 2
antineoplastic agents - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
breast neoplasms (2) 2
breast neoplasms - genetics (2) 2
breast neoplasms - therapy (2) 2
cancer (2) 2
chemotherapy, adjuvant (2) 2
clinical trial, phase iii (2) 2
epirubicin (2) 2
epirubicin - administration & dosage (2) 2
follow-up studies (2) 2
journal article (2) 2
mastectomy (2) 2
multicenter study (2) 2
neoplasm staging (2) 2
poly-adp-ribose binding proteins (2) 2
prognosis (2) 2
proportional hazards models (2) 2
randomized controlled trial (2) 2
statistical analysis (2) 2
treatment outcome (2) 2
administration, oral (1) 1
advanced breast cancer (1) 1
age factors (1) 1
analysis (1) 1
animals (1) 1
anthracycline (1) 1
anthracyclines (1) 1
antibodies, monoclonal, humanized (1) 1
antibodies, monoclonal, humanized - adverse effects (1) 1
antigens, neoplasm (1) 1
antigens, neoplasm - genetics (1) 1
antigens, neoplasm - metabolism (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - metabolism (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
benefit (1) 1
biomarkers, pharmacological (1) 1
biomarkers, tumor - analysis (1) 1
biotechnology (1) 1
breast (1) 1
breast neoplasms - diagnosis (1) 1
breast neoplasms - metabolism (1) 1
breast neoplasms - mortality (1) 1
breast neoplasms - psychology (1) 1
breast neoplasms - surgery (1) 1
cancer therapies (1) 1
carcinoma, ductal, breast (1) 1
carcinoma, ductal, breast - genetics (1) 1
carcinoma, ductal, breast - secondary (1) 1
carcinoma, ductal, breast - therapy (1) 1
cell-line (1) 1
chemotherapy (1) 1
clinical database (1) 1
clinical trial (1) 1
comparative study (1) 1
complementary therapies - adverse effects (1) 1
complementary therapies - statistics & numerical data (1) 1
complementary therapies - utilization (1) 1
cooperative group dbcg (1) 1
cyclophosphamide (1) 1
cyclophosphamide - administration & dosage (1) 1
denmark (1) 1
disease progression (1) 1
dna topoisomerases, type ii (1) 1
dna topoisomerases, type ii - genetics (1) 1
dna topoisomerases, type ii - metabolism (1) 1
dna-binding proteins (1) 1
dna-binding proteins - genetics (1) 1
dna-binding proteins - metabolism (1) 1
dose-response relationship, drug (1) 1
double-blind method (1) 1
doxorubicin (1) 1
drug administration schedule (1) 1
drug therapy (1) 1
endocrine therapy (1) 1
erbb-2 protein (1) 1
estrogen (1) 1
estrogen-receptor (1) 1
ethical aspects (1) 1
experience (1) 1
follow-up (1) 1
formaldehyde (1) 1
gene expression (1) 1
gene expression regulation, neoplastic - drug effects (1) 1
genetic research (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
by Martin, Miguel and Holmes, Frankie A and Ejlertsen, Bent and Delaloge, Suzette and Moy, Beverly and Iwata, Hiroji and von Minckwitz, Gunter and Chia, Stephen K L and Mansi, Janine and Barrios, Carlos H and Gnant, Michael and Tomašević, Zorica and Denduluri, Neelima and Šeparović, Robert and Gokmen, Erhan and Bashford, Anna and Ruiz Borrego, Manuel and Kim, Sung-Bae and Kim, Seung Jin and Jakobsen, Erik Hugger and Ciceniene, Audrone and Inoue, Kenichi and Overkamp, Friedrich and Heijns, Joan B and Armstrong, Anne C and Link, John S and Joy, Anil Abraham and Bryce, Richard and Wong, Alvin and Moran, Susan and Yao, Bin and Xu, Feng and Xu, Binghe and Auerbach, Alan and Buyse, Marc and Chan, Arlene and Harvey, Vernon and Tomek, Rudolf and Robert, Nicholas J and Gore, Ira and Smith, John W and Smith, Julie C and Masuda, Norikazu and Di Sean Kendall, S and Harker, William Graydon and Petrakova, Katarina and Guerrero Zotano, Angel and Simon, Amparo Ruiz and Konstantinovic, Zora Neskovic and Iannotti, Nicholas O and Tassone, Pierfrancesco and Rodriguez, Gladys I and Jáñez Martinez, Noelia and Crespo Massieu, Carmen and Smickoska, Snezana and Somali, Isil and Yilmaz, Ugur and Alonso, Mirta Garcia and Rosales, Adolfo Murias and Cold, Soeren and Knoop, Ann Soegaard and Patt, Debra and Hellerstedt, Beth A and Morales Murillo, Serafin and Mayer, Ingrid A and Means-Powell, Julie Ann and Hui, Rina and Senecal, Francis M and De Boer, Richard Hendry and Shen, Zhenzhou and Luczak, Adam Andrzej and Chui, Joanna W.Y and Chui, Stephen and Tsang, Janice Wing-hang and Lang, Istvan and Rai, Yoshiaki and Hozumi, Yasuo and Ten Tije, Albert J and Bhandari, Manish and Osborne, Cynthia R.C and Ohtani, Shoichiro and Higaki, Kenji and Watanabe, Junichiro and Watanabe, Kenichi and Taguchi, Tetsuya and Taguchi, Kazunori and Takahashi, Masato and Filipovic, Sladjana and Hansen, Vincent L and Rao, Vijayarama Phooshkooru and Gupta, Manish and Petrov, Petar and Coudert, Bruno and Vojnovic, Zeljko and Polya, Zsofia and Miyaki, Toshiko and Yamamoto, Naohito and Brincat, Stephen and Lesniewski-Kmak, Krzysztof and Chmielowska, Ewa and ... and ExteNET Study Grp and ExteNET Study Group
The Lancet Oncology, ISSN 1470-2045, 12/2017, Volume 18, Issue 12, pp. 1688 - 1700
ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, significantly improves 2-year invasive disease-free survival after... 
LAPATINIB | NCCTG N9831 | NSABP B-31 | HERA TRIAL | MULTICENTER | ONCOLOGY | TYROSINE KINASE | FOLLOW-UP | JOINT ANALYSIS | ESTROGEN-RECEPTOR | CHEMOTHERAPY | Breast Neoplasms - surgery | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Mastectomy - methods | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Quinolines - administration & dosage | Dose-Response Relationship, Drug | Time Factors | Neoplasm Invasiveness - pathology | Adult | Female | Chemotherapy, Adjuvant | Antibodies, Monoclonal, Humanized - adverse effects | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Administration, Oral | Japan | Kaplan-Meier Estimate | Proportional Hazards Models | Trastuzumab - adverse effects | Treatment Outcome | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - pathology | Survival Analysis | Breast Neoplasms - mortality | Neoplasm Staging | Quinolines - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial
by Ejlertsen, Bent and Tuxen, Malgorzata K and Jakobsen, Erik Hugger and Jensen, Maj-Britt and Knoop, Ann Soegaard and Højris, Inger and Ewertz, Marianne and Balslev, Eva and Danø, Hella and Vestlev, Peter Michael and Kenholm, Julia and Nielsen, Dorte L and Bechmann, Troels and Andersson, Michael and Cold, Søren and Nielsen, Hanne Melgaard and Maae, Else and Carlsen, Dorte and Mouridsen, Henning T
Journal of Clinical Oncology, ISSN 0732-183X, 08/2017, Volume 35, Issue 23, pp. 2639 - 2646
Purpose Administration of anthracycline and taxane therapy in the adjuvant setting is considered a standard for breast cancer. We evaluated a... 
Carcinoma, Ductal, Breast - genetics | Cyclophosphamide - administration & dosage | Follow-Up Studies | Humans | Menopause | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Breast Neoplasms - therapy | Poly-ADP-Ribose Binding Proteins | Neoplasm Grading | Mastectomy | Adult | Female | Chemotherapy, Adjuvant | Carcinoma, Ductal, Breast - secondary | Antigens, Neoplasm - genetics | Survival Rate | DNA-Binding Proteins - genetics | Carcinoma, Ductal, Breast - therapy | Disease-Free Survival | Taxoids - administration & dosage | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | DNA Topoisomerases, Type II - genetics | Aged | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study
by Buhl, Anna Sofie Kappel and Christensen, Troels Dreier and Christensen, Ib Jarle and Nelausen, Knud Mejer and Balslev, Eva and Knoop, Ann Søegaard and Brix, Eva Harder and Svensson, Else and Glavicic, Vesna and Luczak, Adam and Langkjer, Sven Tyge and Linnet, Søren and Jakobsen, Erik Hugger and Bogovic, Jurij and Ejlertsen, Bent and Rasmussen, Annie and Hansen, Anker and Knudsen, Steen and Nielsen, Dorte and Jensen, Peter Buhl
Breast Cancer Research and Treatment, ISSN 0167-6806, 11/2018, Volume 172, Issue 2, pp. 391 - 400
PurposeAnthracyclines remain a cornerstone in the treatment of primary and advanced breast cancer (BC). This study has evaluated the predictive value of a... 
Epirubicin | Advanced breast cancer | Precision medicine | Predictive biomarker | BENEFIT | THERAPY | ONCOLOGY | PHASE-III | DOXORUBICIN | GUIDELINES | CELL-LINE | Prospective Studies | Humans | Middle Aged | RNA, Messenger - genetics | Biomarkers, Pharmacological | Proportional Hazards Models | Epirubicin - administration & dosage | Breast Neoplasms - drug therapy | Disease Progression | Disease-Free Survival | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Adult | Female | Aged | Retrospective Studies | Gene Expression Regulation, Neoplastic - drug effects | Neoplasm Proteins - genetics | Precision Medicine | Anthracyclines | RNA | Oncology, Experimental | Medical records | Breast cancer | Research | Gene expression | Ethical aspects | Formaldehyde | Analysis | Genetic research | Drug therapy | Cancer | Clinical Trial
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Breast cancer mortality in synchronous bilateral breast cancer patients
by Mejdahl, MK and Wohlfahrt, J and Holm, M and Balslev, E and Knoop, AS and Tjonneland, A and Melbye, M and Kroman, N
BRITISH JOURNAL OF CANCER, ISSN 0007-0920, 04/2019, Volume 120, Issue 7, pp. 761 - 767
BACKGROUND: Evidence suggests that patients with synchronous bilateral breast cancer (SBBC), diagnosed within 4 months, have an inferior prognosis compared to... 
SURVIVAL | ONCOLOGY | PROGNOSIS | CLINICAL DATABASE | COOPERATIVE GROUP DBCG | EXPERIENCE | TREATMENT GUIDELINES | Prognosis | Statistical analysis | Mortality | Breast | Breast cancer | Poisson density functions | Patients | Tumors | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Liposomal cisplatin response prediction in heavily pretreated breast cancer patients: A multigene biomarker in a prospective phase 2 study
by Jakobsen, Erik Hugger and Nielsen, Dorte and Danoe, Hella and Linnet, Soeren and Hansen, Joergen and Lassen, Ulrik Niels and Balslev, Eva and Glavicic, Vesna and Bogovic, Jurij and Knudsen, Steen and Ejlertsen, Bent and Knoop, Ann Søegaard and Buhl, Ulla Hald and Madsen, Mogens Winkel and Buhl, Ida Kappel and Hansen, Anker and Jensen, Thomas and Rasmussen, Annie and Jensen, Peter Buhl and Langkjer, Sven Tyge
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. e13077 - e13077
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Prediction of exemestane benefit in patients with advanced breast cancer based on diagnostic biopsy mRNA analysis
by Christensen, Troels Dreier and Buhl, Anna Sofie Kappel and Christensen, Ib Jarle and Nelausen, Knud Mejer and Balslev, Eva and Knoop, Ann Søegaard and Brix, Eva Harder and Vestlev, Peter Michael and Ejlertsen, Bent and Kumler, Iben and Luczak, Adam and Langkjer, Sven Tyge and Linnet, Soeren and Jakobsen, Erik and Bogovic, Jurij Antonovic and Glavicic, Vesna and Buhl, Ulla Hald and Jensen, Peter Buhl and Knudsen, Steen and Nielsen, Dorte
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. e12532 - e12532
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Status over klinisk anvendte prognostiske og prædiktive faktorer ved allokering til systemisk behandling efter primær cancer mammae
by Knoop, Ann Søegaard and Rasmussen, Birgitte Bruun
Ugeskrift for Laeger, ISSN 0041-5782, 09/2007, Volume 169, Issue 36, pp. 2997 - 2999
Journal Article
Details down arrow
8. Brystkræftpatienters brug af komplementær og alternativ medicin - Effekt og interaktioner
by Damkier, Anette and Paludan-Müller, Christine and Knoop, Ann Søegaard
Ugeskrift for Laeger, ISSN 0041-5782, 09/2007, Volume 169, Issue 37, pp. 3111 - 3114
Journal Article
Details down arrow
9. Prognostic and predictive factors for endocrine treatment in breast carcinoma
by Knoop, Ann Søegaard and Rasmussen, Birgitte Bruun
Ugeskrift for laeger, 09/2007, Volume 169, Issue 36, p. 2997
There is a long tradition for defining prognostic factors in breast carcinoma; the classic ones being lymphnode status, tumor size, malignancy grade, and... 
DNA Topoisomerases, Type II - metabolism | Predictive Value of Tests | Receptors, Estrogen - metabolism | Prognosis | Age Factors | Biomarkers, Tumor - analysis | Humans | Antineoplastic Agents - therapeutic use | Lymphatic Metastasis | Breast Neoplasms - drug therapy | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | DNA-Binding Proteins - metabolism | Poly-ADP-Ribose Binding Proteins | Receptor, Epidermal Growth Factor - metabolism | Antineoplastic Agents - adverse effects | Breast Neoplasms - pathology | Antigens, Neoplasm - metabolism | Female | Breast Neoplasms - diagnosis | Neoplasm Staging
Journal Article
Details down arrow
10. Use of complementary and alternative medicine (CAM) in breast cancer patients. Efficacy and interactions
by Damkier, Anette and Paludan-Müller, Christine and Knoop, Ann Søegaard
Ugeskrift for laeger, 09/2007, Volume 169, Issue 37, p. 3111
At least one third of Danish breast cancer patients use CAM as a supplement to conventional treatment. There is no documentation for the life-prolonging or... 
Humans | Risk Factors | Treatment Outcome | Antineoplastic Agents - therapeutic use | Complementary Therapies - adverse effects | Breast Neoplasms - drug therapy | Antineoplastic Agents - metabolism | Breast Neoplasms - therapy | Animals | Complementary Therapies - utilization | Breast Neoplasms - psychology | Herb-Drug Interactions | Denmark | Quality of Life | Female | Complementary Therapies - statistics & numerical data
Journal Article
Details down arrow
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.